Palbociclib 2HCL (PD-0332991 dihydrochloride), the dihydrochloride salt of Palbociclib, is a highly specific inhibitor of Cdk4 and Cdk6, with IC50 values of 11 nM and 16 nM, respectively. It is a potent antiproliferative agent against retinoblastoma (Rb)-positive tumor cells in vitro, inducing a selective G1 cell cycle arrest and reducing phosphorylation at Ser780 and Ser795 […]

Selumetinib sulfate (AZD6244 sulfate, ARRY-142886 sulfate) is an oral, non-ATP-competitive inhibitor of MEK1/2, with an IC50 of 14 nmol/L against purified MEK1. It exhibits an anti-tumor effect in the HT-29 xenograft model and is used to treat cancer and inflammation.

(3R,4S)-Tofacitinib is a less active enantiomer of Tofacitinib and a first-in-class inhibitor of JAK3 with an IC50 of 1 nM. It is highly efficacious in treating rheumatoid arthritis (RA).

(3R,4S)-Tofacitinib is a less active enantiomer of Tofacitinib and a first-in-class inhibitor of JAK3 with an IC50 of 1 nM. It is highly efficacious in treating rheumatoid arthritis (RA).

(3R,4S)-Tofacitinib is a less active enantiomer of Tofacitinib and a first-in-class inhibitor of JAK3 with an IC50 of 1 nM. It is highly efficacious in treating rheumatoid arthritis (RA).

Darifenacin [(±)-UK-88525] is a potent, specific and competitive M3 selective receptor antagonist (M3 SRA) that has been shown to have high affinity and selectivity for the M3 receptor. It significantly improves major overactive bladder (OAB) symptoms with proven efficacy, tolerability, and safety.

Darifenacin [(±)-UK-88525] is a potent, specific and competitive M3 selective receptor antagonist (M3 SRA) that has been shown to have high affinity and selectivity for the M3 receptor. It significantly improves major overactive bladder (OAB) symptoms with proven efficacy, tolerability, and safety.

(3R,4S)-Tofacitinib is a less active enantiomer of Tofacitinib and a first-in-class inhibitor of JAK3 with an IC50 of 1 nM. It is highly efficacious in treating rheumatoid arthritis (RA).

Darifenacin [(±)-UK-88525] is a potent, specific and competitive M3 selective receptor antagonist (M3 SRA) that has been shown to have high affinity and selectivity for the M3 receptor. It significantly improves major overactive bladder (OAB) symptoms with proven efficacy, tolerability, and safety.

Darifenacin [(±)-UK-88525] is a potent, specific and competitive M3 selective receptor antagonist (M3 SRA) that has been shown to have high affinity and selectivity for the M3 receptor. It significantly improves major overactive bladder (OAB) symptoms with proven efficacy, tolerability, and safety.